Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Insider Sells $570,000.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Noah Goodman sold 5,000 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $114.00, for a total value of $570,000.00. Following the sale, the insider directly owned 50,195 shares in the company, valued at $5,722,230. This trade represents a 9.06% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Noah Goodman also recently made the following trade(s):

• On Monday, June 22nd, Noah Goodman sold 2,500 shares of Kymera Therapeutics stock. The stock was sold at an average price of $99.00, for a total value of $247,500.00.
• On Tuesday, April 14th, Noah Goodman sold 1,347 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.00, for a total value of $121,230.00.
• On Friday, April 10th, Noah Goodman sold 2,000 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.35, for a total value of $174,700.00.
• On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The stock was sold at an average price of $87.50, for a total transaction of $723,100.00.

Kymera Therapeutics Trading Down 7.2%

KYMR stock opened at $108.12 on Friday. The firm has a 50 day moving average of $84.81 and a 200-day moving average of $82.31. Kymera Therapeutics, Inc. has a 12 month low of $36.65 and a 12 month high of $130.05. The firm has a market capitalization of $8.89 billion, a P/E ratio of -30.29 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The business had revenue of $34.37 million for the quarter, compared to analyst estimates of $8.27 million. During the same quarter in the prior year, the firm posted ($0.82) EPS. Kymera Therapeutics’s revenue was up 55.5% on a year-over-year basis. Sell-side analysts predict that Kymera Therapeutics, Inc. will post -3.28 EPS for the current year.

Key Stories Impacting Kymera Therapeutics

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera completed enrollment in its Phase 2b BROADEN2 trial for KT-621 ahead of schedule, accelerating the timeline for topline data to year-end 2026 and lifting optimism about the atopic dermatitis program. Article: Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
• Positive Sentiment: BTIG Research reaffirmed a buy rating on Kymera Therapeutics and set a $134 price target, reinforcing bullish expectations for the stock. Article: Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
• Neutral Sentiment: Kymera appointed Felix J. Baker, Ph.D. as chairman of the board, a leadership change that supports oversight but is less likely to move shares on its own. Article: Kymera Therapeutics Appoints Felix J. Baker, Ph.D. as Chairman of the Board of Directors
• Negative Sentiment: Recent insider selling, including shares sold by Noah Goodman and multiple sales by director Bruce Booth, may raise some caution despite being tied to a pre-arranged trading plan. Article: Insider transaction filing

Wall Street Analyst Weigh In

Several research firms recently commented on KYMR. Citigroup boosted their target price on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Morgan Stanley reiterated an “overweight” rating and set a $119.00 price target on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Canaccord Genuity Group boosted their price objective on Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a report on Friday. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Jefferies Financial Group began coverage on shares of Kymera Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $110.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Kymera Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $118.18.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Baker BROS. Advisors LP boosted its position in Kymera Therapeutics by 30.2% during the 4th quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after buying an additional 2,005,813 shares during the period. Avoro Capital Advisors LLC increased its position in shares of Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after acquiring an additional 1,124,747 shares during the period. Price T Rowe Associates Inc. MD raised its stake in shares of Kymera Therapeutics by 20.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after acquiring an additional 1,061,957 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after acquiring an additional 845,922 shares during the last quarter. Finally, Holocene Advisors LP purchased a new stake in shares of Kymera Therapeutics during the third quarter worth about $47,563,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.